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14.1 Drugs for diabetes 
Prior to discussing the drugs for diabetes, there is a brief discussion of what diabetes is and its 
effects.  In order to understand how some of the drugs work, this eChapter starts with an 
overview of the physiology of the pancreas.  The drugs, including insulin replacement 
therapy, are then discussed in sequence. 
 
14.1.1 Diabetes mellitus 
Diabetes means large volume of urine flowing through.  Diabetes mellitus is when the urine 
is sweet. Diabetes insipidus is when the urine is tasteless.  Diabetes insipidus is a rare 
condition due to impaired renal conservation of water.  Diabetes mellitus is the subject of 
this chapter.   
 
One million Australians have diabetes mellitus, including 20% of those over 65.  Diabetes is 
an enormous burden to the economy, as 10-15% of total health expenditure is on diabetes, of 
which 6% is on diabetes medications and the rest is spent on diabetic complications.  In 
diabetes the underlying syndromes is hyperglycemia, high circulating levels of glucose.  The 
glucose sticks to many sites to interfere with many processes in the body, and this underlies 
the complications with diabetes.  The glucose sticks to haemoglobin, and we use this to 
monitor the ongoing glucose levels in diabetes.  Thus, glycosylated haemoglobin is used as a 
measure of diabetes mellitus, and effective treatments lower the percentage of glycosylated 
haemoglobin.  By sticking to things, hyperglycemia is associated with the altered metabolism 
of lipids, carbohydrates and proteins. 
 
There are two types of diabetes mellitus.  Type I diabetes mellitus (which was previously 
known as insulin-dependent diabetes mellitus (IDDM)) only accounts for 10% of diabetes.  
Type I diabetes is a juvenile onset, autoimmune disease of the pancreatic cells that secrete 
insulin. Once the pancreatic cells are destroyed the individual no longer produces or stores 
insulin.  As insulin is essential to the management of glucose in the body, the resulting high 
levels of glucose can have major effects, if left untreated.   
 
Type 2 diabetes mellitus (previously known as non-insulin dependent diabetes mellitus 
(NIDDM) or maturity onset diabetes) is the common one, and the type of diabetes that is 
epidemic in the Westernized world.  Type 2 diabetes, which accounts for 90% of the diabetes 
mellitus, is more common in adults but can occur in children or adolescents if they are 
overweight or obese. Type 2 diabetes is characterized by low levels of insulin and/or loss 
of insulin sensitivity.  Type 2 diabetes is caused by a variety of genetic and environmental 
factors.  These are multifactorial (involve many factors), heterogenous (vary between 
people), and include obesity, ethnicity, hypertension, and hyperlipidemia. 
 
Diabetes leads to many complications with nearly 60% of diabetic deaths being 
cardiovascular, predominantly myocardial infarction and stroke.  Diabetes also causes 
damage to the kidney and diabetic kidney disease is the most common cause of end-stage 
renal failure.  Diabetes used to also cause a lot of blindness and neuropathy.  Today, if 
diabetes is managed well, these conditions are slow to develop. 
 
14.1.2 Physiology of the pancreas 
Insulin is secreted from a specialized part of the pancreas known as the Islets of Langerhans.  
The beta cells of the islets secrete insulin.  The secretion of insulin is increased by glucose, 
amino acids, and fatty acids.  For glucose, the mechanism is that the glucose is transported 
into beta cells, where it is metabolized (Figure 14.1).  This glucose metabolism leads to ATP 
formation, and ATP closes the K
+
-ATP-dependent channel.  Normally, the K
+
-ATP 
channel is open and K
+
 moves out of the cell through this ion channel, keeping the membrane 
potential low.  When the K
+
-ATP channel is blocked by ATP from the metabolism of 
glucose, the amounts of K
+
 in the cell increases, and this depolarization opens the voltage-
dependent Ca
2+
 channels.  Ca
2+
 entry into the beta cells promotes insulin secretion. 
 
Figure 14.1 Glucose and insulin secretion (Copyright QUT, Sheila Doggrell) 
 
In type 2 diabetes, drugs are used to block the K
+
ATP channel to increase the secretion of 
insulin.  By blocking the K
+
ATP channel, drugs mimic the effect of glucose to increase the 
amounts of K
+
 in the cell, and this depolarization opens the voltage-dependent Ca
2+
 channels.  
Ca
2+
 entry into the beta cells promotes insulin secretion. 
 
During fasting (e.g. between meals) the levels of insulin are low.  During a meal, when 
glucose stimulates the release of insulin, there is a rapid twofold rise in the concentration of 
insulin.  Insulin stimulates the conversion of glucose to glycogen in the liver, the conversion 
of glucose to triglycerides in adipose tissue, and the conversion of amino acids to protein in 
muscle.  Insulin inhibits the breakdown of glycogen, triglycerides and protein, including the 
conversion of amino acids to glucose in the liver, by the process known as gluconeogenesis.  
Thus, insulin is stimulating the clearance of glucose from the plasma, and inhibiting the 
formation of glucose, and thus, the increased levels of glucose after a meal steady decline. 
 
The alpha cells of the pancreas produce glucagon, which is a hormone that has the opposite 
effects to insulin.  For instance it promotes the conversion of glycogen to glucose.  Under 
physiological conditions, insulin and glucagon are not secreted at the same time, as they 
would cancel each other out.  Glucagon is used as a drug to treat severe hypoglycemia 
(unwanted effect of some anti-diabetic drugs). Thus, some of the anti-diabetic drugs not only 
reduce hyperglycemia to normoglycemia, but are capable of reducing normoglycemia to 
hypoglycemia. 
 
14.1.3 Insulin replacement therapy 
The logical treatment for low insulin secretion or low sensitivity to insulin is to replace the 
insulin.  The insulin for replacement is made my recombinant DNA techniques.  Insulin 
replacement therapy is indicated for all subjects with Type 1 diabetes.  Many subjects with 
Type 2 diabetes also end up by producing very little insulin and becoming very insensitive to 
the insulin they produce, and need to use insulin replacement therapy.  However, before that 
changes in diet and oral hypoglycemics (drugs that are active after oral administration, and 
increase the levels of insulin) are initial treatment for Type 2 diabetes.  Insulin is not active 
after oral administration, as it is digested in the gut.  Insulin can be administered in a variety 
of ways: intravenously, intramuscularly, subcutaneously, and by inhalation, but not by oral 
administration, and this is the major drawback to using insulin.   
 
When insulin replacement therapy is used, the goal is to mimic what the endogenous 
insulin would do, if it was there. Endogenous insulin produced by the beta cells of the 
pancreas is injected into the portal vein, which takes in straight to the liver.  Thus, the highest 
concentrations with endogenous insulin will be in the liver, which is very convenient as this 
is the major site of action of insulin.  However, insulin replacement therapy does not mimic 
this.  With all the routes used for insulin (i.v. i.m. s.c. and inhalation), the highest 
concentrations will be at the site of administration, which is not the liver.  Endogenous 
insulin levels are determined by glucose levels, insulin replacement therapy levels is not 
sensitive to plasma levels of glucose.  Thus, insulin replacement therapy is not a perfect 
match for endogenous insulin. 
 
With insulin replacement therapy, we try and match the kinetics of endogenous insulin, by 
using combinations of normal and long-acting preparations of insulin.  Endogenous insulin 
has quite low fasting levels, but when there is a meal, the glucose stimulates insulin secretion 
and there are increased level of insulin.  Pre-breakfast and pre-supper (dinner) injection of 
normal insulin preparations mimics the meal’s effect on the insulin by increasing the insulin 
concentrations.  Long-acting preparations of insulin mimic the fasting levels of endogenous 
insulin by maintaining low levels of insulin. 
 
The meal can be mimicked by insulin injection, which is short acting.  An alternative is to 
use isophane insulin, which is an intermediate acting preparation of insulin.  The fasting 
levels of insulin can be mimicked by insulin glargine, which is a long acting preparation of 
insulin.  Commonly two forms of insulin are combined, so that one injection can be used to 
mimic the fasting and meal levels of insulin.  For instance, insulin injection and isophane 
insulin in various proportions can be used. 
 
The main adverse effect of insulin replacement therapy is hypoglycaemia (low plasma levels 
of glucose).  Hypoglycaemia is characterised by sweating, hunger, palpitations, tremor, 
anxiety, convulsions, and coma.  To prevent hypoglycaemia, regular monitoring of glucose 
levels is used.  The treatment of mildhypoglycemia is to ingest some glucose that is being 
carried.  After a few incidents of hypoglycaemia, diabetics are able to recognise the start, and 
ingest glucose.  If the hypoglycemia is severe, and occurs regularly, it is advisable to have an 
identification card saying you are diabetic or a bracelet that provides the information.  
Thus, at the convulsions/coma state, it will be known to use intravenous glucose or glucagon 
to overcome the hypoglycemia. 
 
There are quite a lot of drug interactions with insulin replacement therapy.  Things that can 
lead to hypoglycemia in combination with insulin replacement therapy include ethanol (ie 
alcohol).  Ethanol inhibits gluconeogenesis, which is the conversion of amino acids to 
glucose, and thus ethanol decreases the levels of glucose.  If a fixed dose of insulin is being 
taken, and ethanol is also taken, there may be excessive reductions in the levels of glucose, 
which may result in hypoglycemia.  Aspirin increases the sensitivity of the pancreas to 
glucose, thereby increasing the secretion of any remaining insulin to reduce levels of glucose.  
Thus, in type 2 diabetes, where there is still some endogenous insulin, the combination of 
aspirin and insulin replacement therapy may lead to hypoglycemia. 
 
A group of drugs that may cause hypoglycemia in combination with insulin replacement 
therapy are the β-adrenoceptor antagonists.  Adrenaline is secreted from the adrenal 
medulla and stimulates β-adrenoceptors that promote gluconeogenesis, the conversion of 
amino acid to glucose, and glycogenolysis, which is the conversion of glycogen to glucose.  
The β-adrenoceptor antagonists prevent these effects of adrenaline, and therefore reduce the 
levels of glucose.  The reduced levels of glucose in combination with insulin replacement 
therapy can lead to hypoglycemia.  
 
Conversely, when the levels of adrenaline are high, as in the fight and flight response, there 
will be increased levels of glucose, and the replacement therapy may not be sufficient to 
decrease the levels of glucose, leading to hyperglycemia (high levels of glucose).  
Glucocorticoids do a lot of things, besides being anti-inflammatory.  For instance, they have 
a permissive action to increase the ability of adrenaline to generate glucose.  Thus, the 
glucocorticoids may lead to hyperglycemia in combination with insulin replacement therapy. 
 
For type 2 diabetes, a number of drugs may be used prior to insulin replacement therapy.  
These include metformin, acarbose, sulfonylureas, glitazones, exenatide and dipeptidyl 
peptidase-4 inhibitors. 
 
14.1.4 Metformin 
Despite the fact that metformin has been used in type 2 diabetes for many years, the 
mechanism of action is still not clear.  We do know the pharmacodynamic actions that 
follow.  Metformin inhibits gluconeogenesis, which is the conversion of amino acids to 
glucose in the liver.  Metformin increases the sensitivity to insulin in type 2 diabetes, and 
where there is low sensitivity to insulin, this leads to increased glucose uptake.  Metformin is 
orally active, and commonly used in the treatment of type 2 diabetes.  Metformin is anti-
hyperglycemic, it reduces hyperglycemia to normoglycemia.  Metformin is not hypoglycemic 
i.e. it does not reduce normoglycemia to hypoglycemia.  Thus, hypoglycemic adverse effects 
are rare with metformin.  The most common unwanted effects of metformin are 
gastrointestinal disturbances, such as nausea and diarrhoea.  Lactic acidosis is a rae, but often 
fatal, side effect that may occur when contraindications to its use are overlooked (eg kidney 
impairment).  One advantage of metformin over some of the anti-diabetic drugs is that there 
is no weight gain with metformin.  In contrast, insulin replacement therapy and the 
sulphonylureas commonly cause weight gain, which tends to make the diabetes worse. 
 
14.1.5 Acarbose 
Carbohydrates are broken down to glucose in the gut by the enzyme α-glucosidase, and the 
glucose is absorbed.   Acarbose is an inhibitor of α-glucosidase, thereby inhibiting the 
formation of glucose in the gut.  Acarbose is active after oral administration, and is used in 
the treatment of Type 2 diabetes only.  By inhibiting the formation of glucose in the gut, 
acarbose leads to reduced absorption of glucose.  Hopefully, the levels of glucose will be 
reduced to a level that can be handled by the remaining insulin.  The use of acarbose 
produces extra carbohydrates in the faeces, which leads to flatulence and diarrhoea.  
Acarbose has a different mechanism of action to metformin, which means it can be used with 
metformin to have an additive effect on plasma glucose levels. 
 
14.1.6 Sulfonylureas  
The sulfonylureas are a group of oral hypoglycemic agents, which includes glibenclamide.  
The sulfonylureas inhibit the K
+
ATP channel in the pancreatic beta cells to increase insulin 
secretion (Figure 14.1).  The sulfonylureas are active after oral administration and are given 
orally once or twice daily, which is a major advantage over insulin.  Their disadvantage over 
insulin is that they are not effective in type 1 diabetes, as they require the presence of insulin 
to work.  The major adverse effect of the sulfonylureas is hypoglycemia, and the 
hypoglycemia is enhanced by alcohol.  Thus, as with insulin, there is a need to check plasma 
glucose regularly to make sure there is no hypoglycemia and that the glucose levels are under 
control.  Unfortunately, the sulfonylureas cause a weight gain of a few kilograms, which 
tends to counter some of the benefit with these agents.  The oral sulfonylureas may become 
less effective with time, this is due to the progression of beta-cell failure or of the insulin 
resistance, making less endogenous insulin available or making the available insulin less 
effective.   When this happens, the type 2 diabetic, may have to proceed to insulin 
replacement therapy. 
 
14.1.7 Glitazones 
An example of a glitazone is pioglitazone.  The glitazones stimulate the nuclear receptor 
peroxisome proliferation-activate receptor-γ (PPARγ), to modulate the levels of a number of 
proteins.  This modulation leads to a reduced glucose output from liver (from glycogen), an 
increase in glucose uptake into muscle, and a reduced insulin resistance.  All of these effects 
combine to decrease plasma glucose.  The glitazones are active after oral administration, and 
are used in type 2 diabetes.  The major adverse effects of the glitazones are weight gain, 
oedema and anaemia.  Hypoglycemia is not usually a problem with the glitazones. 
 
14.1.8 Glucagon-like peptide-1, exenatide and sitagliptin 
Recently, there have been some very interesting findings relating to the treatment of diabetes, 
and they stem from the discovery of a new hormone, known as Glucagon-Like Peptide-1 
(GLP-1).  GLP-1 is produced by the gut, and has a major role in controlling glucose levels.  
GLP-1 stimulates insulin secretion, and inhibits glucagon secretion, both of which will lead 
to a decrease in glucose levels. 
 
This discovery led to a new treatment for diabetes, exenatide.  Exenatide is a peptide agonist 
at GLP-1 receptors which mimics the effects of GLP-1, and so it stimulates insulin secretion 
while inhibiting glucagon secretion.  Exenatide is used subcutaneously, prior to a meal.  
Exenatide is used when there is a lack of control of type 2 diabetes with treatment with 
metformin and a sulfonylurea (glibenclamide).  In time, exenatide may replace these agents 
in the treatment of type 2 diabetes.  Hypoglycemia is an unwanted effect with exenatide.  
 
Glucagon-Like Peptide-1 (GLP-1) is broken down, which leads to inactivation, by the 
enzyme dipeptidyl peptidase-4.  Sitagliptin is an inhibitor of dipeptidyl peptidase-4, and 
inhibition of the enzymes leads to the build up of GLP-1.  Thus, the end result with sitagliptin 
is to mimic the effects of GLP-1 to increase insulin secretion and inhibit glucagon secretion.  
Sitagliptin is active after oral administration, and is increasingly often used in combination 
with other anti-diabetic drugs such as metformin or sulfonylurea (glibenclamide) or 
pioglitazone.  Sitagliptin is capable to causing the adverse effect of hypoglycaemia but this 
occurs mainly when they are used with a sulfonylurea. 
 
14.2 Drugs for obesity 
 
14.2.1 Introduction 
Obesity is derived from the Body Mass Index (BMI), which is body weight in kilograms 
divided by square of height in metres (kg/m
2
).  If you have a BMI of 30 kg/m
2
 or more, you 
are obese.  A BMI in the range of 25-30 kg/m
2
 is considered to be overweight.  Obesity is a 
risk factor for many disorders.  Thus, obese people are more likely to develop diabetes or the 
metabolic syndrome.  The metabolic syndrome is often a precursor to diabetes, and is a 
combination of obesity, raised triglycerides plasma levels, raised plasma glucose levels and 
hypertension.  Obesity, the metabolic syndrome and diabetes are, in turn, risk factors for 
cardiovascular diseases such as atherosclerosis, hypertension, and venous thrombosis (all of 
which are risk factors for angina and heart attacks).  Obesity, the metabolic syndrome and 
diabetes are also risk factors for cerebrovascular disease such as stroke.  
 
Obesity is now recognised as a disease, and not necessarily a character flaw.  There is a 
genetic contribution to obesity, which varies from person to person.  There are also 
environmental factors that contribute to obesity, and these include an increased caloric 
intake and decreased physical activity. 
 
Obesity should be managed with diet and exercise.  When diet and exercise do not work 
alone, they should be used in combination with pharmacotherapy.  There are two approaches 
to reducing body weight.  The first is to decrease energy intake, and this can be achieved by 
dieting or by using certain drugs.  The second is to increase energy expenditure, and this can 
be achieved by physical activity or by using certain drugs.   
 
Even relatively small reductions in body weight are good for you.  Thus, a 5-10% weight loss 
leads to about a 60% reduction in the rate of type 2 diabetes. 
 
14.2.2 Amphetamine 
Amphetamine abusers are thin.  Amphetamine releases noradrenaline (NA), dopamine (DA) 
and 5-hydroxytryptamine (5-HT) from their respective neurones.  This release of 
neurotransmitters leads to increased levels in the synapse, and increased stimulation of their 
respective receptors.  In the central nervous system (CNS), the release of DA is associated 
with the central stimulant effect, for which amphetamines are abused.  In the CNS, the 
release of NA and 5-HT is associated with the anorectic effect.  Thus, if the anorectic effects 
of amphetamine could be separated from the central stimulant, we would have a useful 
anorectic drug.  This has been achieved to a certain extent with phentermine. 
 
14.2.3 Phentermine  
Phentermine releases NA from nerves, with a lesser ability to release DA and 5-HT.  Thus, 
phentermine is anorexic without causing a major central stimulation.  Presently, this drug is 
available for short-term use in Australia: there use is limited to a maximum 12 weeks.  This is 
primarily to prevent people becoming dependent on the remaining central stimulation effect.  
Clinical trials show that phentermine can cause about a 8% weight loss over a year.  
 
The ability of phentermine to release NA is not limited to the CNS; this drug also release NA 
from sympathetic nervous system (SNS).  This release of NA from the SNS underlies the 
contraindications to use of these agents.  Thus, phentermine is contraindicated in 
cardiovascular disease especially hypertension, hyperthyroidism, and cerebrovascular 
disease. 
 
The adverse effects of phentermine are due to the remaining small amount of central 
stimulation.  Thus, common adverse effects with phentermine and diethylpropion include 
insomnia, restlessness and nervousness.  
 
14.2.4 Orlistat 
Orlistat inhibits pancreatic lipase to inhibit the absorption of fat.  The pancreas produces a 
lipase that breaks down triglycerides in the gut to free fatty acids.  When free fatty acids are 
formed they are absorbed and go into the circulation as cholesterol and triglycerides.  By 
inhibiting this absorption, orlistat reduces the intake of fat, and this leads to weight reduction.  
Over 12 months, there is a 5-10% loss in body weight with orlistat.  Orlistat treatment has 
also been shown to decrease plasma triglycerides and LDL-cholesterol, while increasing 
HDL-cholesterol. 
 
The intact triglycerides that are not absorbed remain in the gut and are excreted in the faeces.  
These extra triglycerides cause the adverse effects with orlistat, which are flatus with 
discharge, oily spotting, faecal urgency and oily stools. 
 
The fat soluble vitamins (A, D and E) are absorbed in fat, and there was some concern that 
the use of orlistat may decrease the absorption of these vitamins, and lead to vitamin 
deficiency.  However, the plasma levels of the fat soluble vitamins are reduced but remain 
within normal limits during orlistat treatment, and vitamin supplementation is not required.  
 
